Taysha Gene Therapies, Inc. Detailed Financials

Full historical quarterly statements

Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue05.5M02.0M2.3M2.0M1.8M1.1M
Cost of Goods Sold295K299K286K00000
Gross Profit-295K5.2M-286K2.0M2.3M2.0M1.8M1.1M
R&D Expenses33.8M24.7M25.5M20.1M15.6M15.3M14.9M15.1M
Operating Expenses43.2M33.5M33.7M28.7M23.7M22.0M27.7M22.4M
Operating Income-43.5M-28.3M-34.0M-26.8M-21.4M-19.9M-25.9M-21.3M
Other Income / Gains1.1M449K1.3M-129K-108K1.1M374K371K
Net Income-42.4M-27.9M-32.7M-26.9M-21.5M-18.8M-25.5M-20.9M
EPS (Diluted)-0.12-0.08-0.093-0.09-0.08-0.092-0.095-0.09
Reported CurrencyUSDUSDUSDUSDUSDUSDUSDUSD
Gross Profit Ratio00.94501.001.001.001.001.00
General And Administrative Expenses9.7M8.8M8.3M8.6M8.2M6.6M7.9M7.3M
Selling And Marketing Expenses00000000
Selling General And Administrative Expenses9.7M8.8M8.3M8.6M8.2M6.6M7.9M7.3M
Other Expenses-295K000004.8M0
Cost And Expenses43.5M33.8M34.0M28.7M23.7M22.0M27.7M22.4M
Interest Income2.6M2.9M3.2M1.9M1.3M1.7M2.1M1.4M
Interest Expense9K12K15K17K19K22K24K27K
Depreciation And Amortization295K299K286K277K283K304K294K322K
Ebitda-42.1M-28.0M-32.4M-26.6M-21.2M-18.5M-25.2M-20.6M
Ebitdaratio0-5.1050-13.388-9.221-9.129-14.097-18.506
Operating Income Ratio0-5.160-13.471-9.305-9.858-14.484-19.154
Income Before Tax-42.4M-27.9M-32.7M-26.9M-21.5M-18.8M-25.5M-20.9M
Income Before Tax Ratio0-5.0780-13.536-9.352-9.29-14.275-18.82
Income Tax Expense00000000
Net Income Ratio0-5.0780-13.536-9.352-9.29-14.275-18.82
Epsdiluted-0.12-0.08-0.093-0.09-0.08-0.092-0.095-0.09
Weighted Average Shs Out366.6M319.7M353.3M298.0M269.3M204.9M267.8M232.8M
Weighted Average Shs Out Dil366.6M319.7M353.3M298.0M269.3M204.9M267.8M232.8M